Shenzhen, November 05, 2022
IONOVA Life Science announces that data from a Phase I first-in-human study of INV-1120, a novel EP4 inhibitor, will be presented during the SITC Congress 2022.
Title: Preliminary safety, efficacy and pharmacokinetic results of the EP4 antagonist INV-1120 from a first-in-human study in subjects with advanced solid tumors
Abstract Number: 597
Presentation day: Poster Hall November 10, 2022, 9:00 am to 9:00pm
Poster Number: 597
First Author: John Sarantopoulos, Mays Cancer Center, University of Texas, San Antonio Health Science Center
According to Dr. Johannes Nippgen, Chief Medical Officer of IONOVA, "we are very excited about this unique opportunity to show the first clinical data of our compound publicly and confirm the superior profile as single agent."
INV-1120 is a highly potent, highly selective, and orally available EP4 antagonist designed to modulate the tumor microenvironment. EP4 antagonists have shown to increase T cell infiltration and the level of M1 type macrophages in tumors, contributing to increased anti-cancer immune response in preclinical tumor models.
IONOVA is a clinical-stage biotech company focused on the discovery and development of innovative cancer medicines especially in the field of precision medicine and immunotherapy.